Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695501 vs Humira in Crohn's Disease
NCT02871635Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2016
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of adalimumab-adbm in Crohn's disease (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at 4 weeks. Started Sep 2016; status: completed.
02
Drugs
adalimumab-adbm
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02871635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871635.